Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

Publication Detail

Title: PTUPB ameliorates high-fat diet-induced non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in mice.

Authors: Sun, Chen-Chen; Zhang, Chen-Yu; Duan, Jia-Xi; Guan, Xin-Xin; Yang, Hui-Hui; Jiang, Hui-Ling; Hammock, Bruce D; Hwang, Sung Hee; Zhou, Yong; Guan, Cha-Xiang; Liu, Shao-Kun; Zhang, Jun

Published In Biochem Biophys Res Commun, (2020 03 19)

Abstract: Non-alcoholic fatty liver disease (NAFLD) affects 25% of the global adult population, and no effective pharmacological treatment has been found. Products of arachidonic acid metabolism have been developed into a novel therapy for metabolic syndrome and diabetes. It has been demonstrated that protective actions of a novel dual cyclooxygenase-2 (COX-2) and soluble epoxide hydrolase (sEH) inhibitor, PTUPB, on the metabolic abnormalities. Here, we investigated the effects of PTUPB on hepatic steatosis in high-fat diet (HFD)-induced obese mice, as well as in hepatocytes in vitro. We found that PTUPB treatment reduced body weight, liver weight, liver triglyceride and cholesterol content, and the expression of lipolytic/lipogenic and lipid uptake related genes (Acc, Cd36, and Cidec) in HFD mice. In addition, PTUPB treatment arrested fibrotic progression with a decrease of collagen deposition and expression of Col1a1, Col1a3, and α-SMA. In vitro, PTUPB decreased palmitic acid-induced lipid deposition and downregulation of lipolytic/lipogenic genes (Acc and Cd36) in hepatocytes. Additionally, we found that PTUPB reduced the production of pro-inflammatory cytokines and suppressed the NLRP3 inflammasome activation in HFD mice and hepatocytes. In conclusion, dual inhibition of COX-2/sEH attenuates hepatic steatosis by inhibiting the NLRP3 inflammasome activation. PTUPB might be a promising potential therapy for liver steatosis associated with obesity.

PubMed ID: 31973813 Exiting the NIEHS site

MeSH Terms: Animals; Cell Line; Cyclooxygenase 2/metabolism; Diet, High-Fat/adverse effects*; Epoxide Hydrolases/metabolism; Inflammasomes/metabolism*; Inflammation/pathology; Liver Cirrhosis/enzymology; Liver Cirrhosis/pathology; Liver/enzymology; Liver/pathology; Male; Mice, Inbred C57BL; NLR Family, Pyrin Domain-Containing 3 Protein/metabolism*; Non-alcoholic Fatty Liver Disease/drug therapy*; Non-alcoholic Fatty Liver Disease/enzymology; Non-alcoholic Fatty Liver Disease/metabolism*; Non-alcoholic Fatty Liver Disease/pathology

to Top